• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $104 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-61 Mln

Chimerix Inc. (CMRX) Share Price

$1.17

As on 01-Mar-2024 16:14 EST

up-down-arrow $0.021.74%

  • Prev Close info

    $1.15

  • Day's Openinfo

    $1.17

  • Today's Highinfo

    $1.22

  • Today's Lowinfo

    $1.10

  • Today's Volumeinfo

    714,068

  • 52 Week rangeinfo

    $0.88 - 1.77

Please wait...

Chimerix Inc. (CMRX) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Chimerix (CMRX)
21.88 24.95 20.62 -25.95 -50.78 -10.44 -24.71
S&P BSE Sensex*
2.17 3.02 9.37 24.23 13.97 15.40 13.33
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 01-Mar-2024  |  *As on 02-Mar-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Chimerix (CMRX)
-48.39 -71.07 33.13 137.93 -21.01 -44.31 0.65
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Chimerix Inc. (CMRX) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Chimerix Inc. (CMRX)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Chimerix Inc. (CMRX)

        CEO, President & Director

        Mr. Michael T. Andriole M.B.A.

        Chief Medical Officer

        Dr. Allen S. Melemed M.B.A., M.D.

        Headquarters

        Durham, NC

        FAQs for Chimerix Inc. (CMRX)

        The total asset value of Chimerix Inc. (CMRX) stood at $ 213 Mln as on 31-Dec-23

        The share price of Chimerix Inc. (CMRX) is $1.17 (NASDAQ) as of 01-Mar-2024 16:14 EST. Chimerix Inc. (CMRX) has given a return of -50.78% in the last 3 years.

        Chimerix Inc. (CMRX) has a market capitalisation of $ 104 Mln as on 01-Mar-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Chimerix Inc. (CMRX) is 0.50 times as on 01-Mar-2024, a -0.83% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Chimerix Inc. (CMRX) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Chimerix Inc. (CMRX) and enter the required number of quantities and click on buy to purchase the shares of Chimerix Inc. (CMRX).

        Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors, which harbor the H3 K27M mutation in glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2 (COVID-19) infection. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

        The CEO & director of Mr. Michael T. Andriole M.B.A.. is Chimerix Inc. (CMRX), and CFO & Sr. VP is Dr. Allen S. Melemed M.B.A., M.D..

        The promoters of Chimerix Inc. (CMRX) have pledged 0% of the total equity as on Sep-23.

        Chimerix Inc. (CMRX) Ratios
        Return on equity(%)
        --
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        --
        Dividend yield(%)
        --

        No, TTM profit after tax of Chimerix Inc. (CMRX) was $-61 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $104.05 Mln
        • Revenue (TTM)revenue-information $1.13 Mln
        • Earnings (TTM) earning-information $-60.91 Mln
        • Cash date-information $194.48 Mln
        • Total Debt info $1.47 Mln
        • Insider's Holding 6.45%
        • Liquidity liquidity High
        • 52 Week range week-range $0.88 - 1.77
        • Shares outstanding share-outstanding 88,929,296
        • 10 Years Aggregate:

          CFO: $-641.74 Mln

          EBITDA: $-816.30 Mln

          Net Profit: $-775.03 Mln

        About The Company

        • IPO Date 11-Apr-2013
        • CEO, President & Director Mr. Michael T. Andriole M.B.A.
        • Chief Medical Officer Dr. Allen S. Melemed M.B.A., M.D.
        • Listing key-listing NASDAQ: CMRX
        • Country United States
        • Headquarters headquarters Durham, NC
        • Website website https://www.chimerix.com
        • Business

          Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors, which harbor the...  H3 K27M mutation in glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2 (COVID-19) infection. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.  Read more

        share-fund-plan-icon